SCYNEXIS and Partners Secure $7 Million Annual NIH Grant for Novel Antifungal Development
SCYNEXIS Inc. and partners have secured a $7 million annual grant from the NIH to develop novel antifungal compounds. The five-year grant supports a consortium led by Hackensack Meridian CDI and Johns Hopkins Bloomberg School of Public Health. The funding will aid the Center of Excellence in Translational Research in advancing therapeutics for resistant fungal infections, including SCYNEXIS's next-generation fungerp candidates.
SCYNEXIS Inc. announced that a novel series of antifungal compounds from its proprietary triterpenoid antifungal platform will be part of a new federally funded research initiative. The five-year federal grant, totaling approximately $7 million annually, was awarded to a consortium led by researchers from the Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health, with SCYNEXIS and other academic and commercial collaborators participating. The funding, provided by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), will support the Center of Excellence in Translational Research (CETR) and accelerate the development of new therapeutics for resistant fungal infections, including SCYNEXIS’s next-generation fungerp candidates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
